SeaStar Medical (NASDAQ:ICU) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of SeaStar Medical (NASDAQ:ICU – Free Report) from a sell rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.00.

Get SeaStar Medical alerts:

Get Our Latest Stock Report on SeaStar Medical

SeaStar Medical Price Performance

ICU opened at $3.58 on Friday. SeaStar Medical has a one year low of $2.07 and a one year high of $12.50. The company has a fifty day moving average price of $3.36 and a 200-day moving average price of $3.54. The firm has a market capitalization of $15.79 million, a P/E ratio of -0.92 and a beta of -1.05.

SeaStar Medical (NASDAQ:ICU – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.06. The business had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.49 million. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%. On average, analysts expect that SeaStar Medical will post -3.66 earnings per share for the current year.

About SeaStar Medical

(Get Free Report)

SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company focused on developing therapies that address excessive inflammation and immune-system activation in critically ill patients. The company’s approach is designed to target activated immune cells in the bloodstream, which can contribute to organ damage and complications associated with severe illness.

SeaStar Medical’s lead product is Quelimmune, formerly known as the Selective Cytopheretic Device (SCD). The extracorporeal blood-purification device is used with continuous kidney replacement therapy to selectively target pro-inflammatory cells while blood circulates outside the body.

Read More

• Five stocks we like better than SeaStar Medical
• Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
• Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
• AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
• Insiders Signal Deep Value In DICK’s Sporting Goods

Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.